Physician profile
Kyle Legrand
NPI 1972820280
$163.71
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.33 · 2020: $12.25 · 2021: $37.04 · 2022: $42.09.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $41.94 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.24 | 2020-2022 | |
| Astellas Pharma US INC | $19.65 | 2019 | |
| Medtronic Vascular, INC. | $15.17 | 2019 | |
| Amgen INC. | $14.27 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.44 | 2019 | |
| Merck Sharp & Dohme LLC | $12.20 | 2021 | |
| Medtronic USA, INC. | $10.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Legrand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.